MARKET

MYOV

MYOV

MYOVANT SCIENCES
NYSE

Real-time Quotes | Nasdaq Last Sale

10.68
-0.49
-4.39%
Opening 11:20 02/25 EST
OPEN
11.14
PREV CLOSE
11.17
HIGH
11.32
LOW
10.66
VOLUME
734.88K
TURNOVER
--
52 WEEK HIGH
26.02
52 WEEK LOW
4.140
MARKET CAP
958.94M
P/E (TTM)
-2.8733
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MYOV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MYOV stock price target is 24.83 with a high estimate of 34.00 and a low estimate of 15.00.

EPS

MYOV News

More
  • Myovant Sciences to Present at Upcoming March Investor Conferences
  • GlobeNewswire · 2h ago
  • Is the Options Market Predicting a Spike in Myovant (MYOV) Stock?
  • Zacks · 4d ago
  • Tyro Capital Management 2019 Annual Commentary
  • Seeking Alpha - Article · 5d ago
  • Myovant's Uterine Fibroid Drug Relugolix Produces Positive Data in a Long-Term Study
  • MotleyFool.com · 02/10 21:32

Industry

Biotechnology & Medical Research
-2.54%
Pharmaceuticals & Medical Research
-1.58%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About MYOV

Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The Company is developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility.
More

Webull offers kinds of Myovant Sciences Ltd stock information, including NYSE:MYOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYOV stock news, and many more online research tools to help you make informed decisions.